Oramed Pharmaceuticals Inc(ORMP) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | RUT | P/E | 1.01 | EPS (ttm) | 4.11 | Insider Own | 24.68% | Shs Outstand | 41.3M | Perf Week | 0.48% |
| Market Cap | 0.17B | Forward P/E | - | EPS next Y | - | Insider Trans | -2.47% | Shs Float | 31.3M | Perf Month | -11.3% |
| Enterprise Value | 0.12B | PEG | - | EPS next Q | 0.43 | Inst Own | 40.46% | Short Float | 4.63% | Perf Quarter | 0.97% |
| Income | 0.17B | P/S | - | EPS this Y | 246.51% | Inst Trans | 13.84% | Short Ratio | 7.87 | Perf Half Y | 8.33% |
| Sales | 0.00B | P/B | 0.54 | EPS next 5Y | - | ROA | 65.52% | Short Interest | 1.45M | Perf YTD | 56.57% |
| Book/sh | 7.68 | P/C | 3.42 | EPS past 3/5Y | - | ROE | 73.75% | 52W High | -23.95% ($5.47) | Perf Year | 89.08% |
| Cash/sh | 1.22 | P/FCF | - | Sales past 3/5Y | -9.55% -5.9% | ROIC | 54.74% | 52W Low | 113.51% ($1.95) | Perf 3Y | 141.21% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 802.72% | Gross Margin | - | Volatility(W/M) | 2.93% 3.61% | Perf 5Y | -81% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | -100% | Oper. Margin | - | ATR (14) | 0.15 | Perf 10Y | -33.15% |
| Dividend Ex-Date | 2026/1/16 | Quick Ratio | 4.98 | EPS Q/Q | 489.58% | Profit Margin | - | RSI (14) | 40.27 | Recom | 3 |
| Dividend Gr. 3/5Y | - | Current Ratio | 4.98 | Sales Q/Q | - | SMA20 | -1.69% ($4.23) | Beta | 1.29 | Target Price | $7 |
| Payout | - | Debt/Eq | 0 | Earnings | 2026/08/12 | SMA50 | -9.45% ($4.59) | Rel Volume | 0.3 | Prev Close | $4.16 |
| Employees | 13 | LT Debt/Eq | 0 | EPS/Sales Surpr. | 541.86% - | SMA200 | 3.43% ($4.02) | Avg Volume(3M) | 0.18M | Price | $4.16 |
| IPO | 2004/3/19 | Option/Short | Yes/Yes | Trades | 758 | Volume | 55,709 | Change | - |
💊 A clinical-stage biotech company developing oral insulin and oral obesity/diabetes peptide candidates based on oral protein drug delivery technology. The company focuses on technology that delivers insulin and peptides in pill form rather than by injection, is headquartered in the United States, and is conducting global clinical trials.
Over the past 1 year, roughly in the middle
24% below its 1-year high.
Traded less than usual. That is 30% of its average volume.
ORMP earns at a steady pace
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +246.5% this year.
Tap to view numbers
Within its industry, it looks cheap
For a company earning $100 a year, you would pay $101. Peers typically go for $1,452. Compared with its own 1-year average, it is 64% cheaper now.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 3 quarters.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Hold.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -81.0%. The S&P 500 did +69% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership looks stable
Institutions hold 40.5%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #316 of 594 in the industry
Based on market cap of $173M.
PEPG#314 PepGen Inc $175M PER - 
MDWD#315 MediWound Ltd $175M PER - ORMP#316 Oramed Pharmaceuticals Inc $173M PER 1.0 
ABOS#317 Acumen Pharmaceuticals Inc $172M PER - 
ANTX#318 AN2 Therapeutics Inc $171M PER - 
FAQ
What kind of company is ORMP?
ORMP belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of ORMP?
The market cap of ORMP is approximately $173M, ranking 4,133 within its sector.
What is the P/E ratio of ORMP?
ORMP has a P/E ratio of approximately 1.0x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for ORMP?
ORMP has recorded a 52-week high of $5.47 and a low of $1.95.
